Large Molecule Bioanalytical Technologies Market Size - By Offering, Technology, Application, End-use & Forecast, 2024 - 2032

PUBLISHED: February 29, 2024

PAGES: 160 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Global Large Molecule Bioanalytical Technologies Market will record a 10.4% CAGR from 2024 to 2032. Rising R&D expenditure, particularly in biologics development, fuels the demand for advanced analytical tools. Ongoing technological advancements enhance the sensitivity and efficiency of large molecule analysis, catering to the complex needs of biologics characterization. This synergy of increased R&D investment, an expanding biologics landscape, and continuous innovation will propel the market, providing critical solutions for the pharmaceutical, biotech, and research sectors globally.

For instance, in January 2024, Agilent Technologies introduced the Agilent ProteoAnalyzer system, an automated CE platform. It streamlines and enhances the analysis of intricate protein mixtures, crucial in various sectors such as pharmaceuticals, biotech, food analysis, and academia, optimizing analytical workflows for these industries.

The large molecule bioanalytical technologies industry is segmented based on offering, technology, application, end use, and region.

The contract research organization segment will capture a considerable industry share by 2032 due to CROs' specialized expertise, advanced technologies, and streamlined processes for developing and analyzing complex biologics. As pharmaceutical and biotech companies increasingly outsource their research and development activities, CROs emerge as pivotal partners, offering cost-effective solutions and accelerated timelines. Their comprehensive services, spanning from preclinical development to clinical trials, position them as key players driving innovation and efficiency in the large molecule bioanalytical landscape.

The large molecule bioanalytical technologies market from the cell and gene therapy segment will accumulate substantial gains by 2032, fueled by the surge in the development and adoption of these revolutionary therapies. Cell and gene therapies necessitate intricate bioanalytical tools for precise characterization and monitoring, driving the demand for specialized technologies. With a focus on personalized medicine and advancements in biotechnology, the cell and gene therapy segment will experience substantial growth, solidifying its position as a key player in the large molecule bioanalytical technologies market.

Europe large molecule bioanalytical technologies industry size will exhibit a remarkable CAGR from 2024 to 2032, attributed to the region's robust pharmaceutical and biotechnology sectors, fostering a culture of innovation and research. European countries house numerous biopharmaceutical companies and academic institutions specializing in large molecule analysis. Additionally, stringent regulatory frameworks and investments in cutting-edge technologies bolster Europe's position in this market. With a commitment to advancing bioanalytical techniques, Europe will emerge as a substantial contributor to the market expansion.

Product Code: 8333

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing demand for biologics & biosimilars
  - 3.2.1.2 Rising advancements in bioanalytical technology
  - 3.2.1.3 Increasing prevalence of chronic diseases
  - 3.2.1.4 Increasing research and development in the omics sector
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High costs associated with these technologies
  - 3.2.2.2 Lack of standardization and validation
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter's analysis
- 3.6.1 Supplier power
- 3.6.2 Buyer power
- 3.6.3 Threat of new entrants
- 3.6.4 Threat of substitutes
- 3.6.5 Industry rivalry
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Offering, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Products
- 5.2.1 Consumables & accessories
- 5.2.2 Instruments
- 5.2.3 Reagents & kits
5.3 Service

Chapter 6 Market Estimates and Forecast, By Technology, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Chromatography
6.3 Mass spectrometry
6.4 ELISA
6.5 Electrophoresis
6.6 Polymerase chain reaction
6.7 Western blot
6.8 Flow cytometry
6.9 Spectrometer
6.10 Other technologies

Chapter 7 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Biologics
7.3 Oligonucleotide derived drugs & molecules
7.4 Viral vector
7.5 Cell & gene therapy
7.6 Nanoparticles & polymers
7.7 Disease diagnosis
7.8 Other applications

Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 Pharmaceutical & biotechnology companies
8.3 Contract research organizations
8.4 Research & academic institutes
8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Italy
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa